Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
92 shown of 9,780 total abstracts
  1. Abstract 92102026-04-04 · 13:45 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    C. Saura, L. Paz-Ares, M. Reck · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  2. Abstract 93792026-04-01 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-233 study)
    N. Rizvi, S. Modi · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  3. Abstract 93352026-04-01 · 15:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    J. Cortes, P. Schmid, M. Krop, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  4. Abstract 93292026-04-04 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-422 study)
    M. Reck, C. Saura · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  5. Abstract 94662026-04-03 · 18:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-1
    S. Peters, M. Krop, S. Antonia · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  6. Abstract 93912026-04-04 · 14:15 CT · S100A
    IMpower-930: Tecentriq (atezolizumab) 3L+ in NSCLC
    M.C. Garassino, A. Spira, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 94822026-04-04 · 19:30 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-443
    J. Cortes, S. Peters, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 96792026-04-03 · 19:30 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    C. Robert, E. Winer, M. Reck, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  9. Abstract 91342026-04-04 · 18:15 CT · Arie Crown Theater
    IMpower-587: Tecentriq (atezolizumab) maintenance in NSCLC
    C. Saura, L. Paz-Ares, S. Antonia · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 98352026-04-01 · 14:30 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-652
    A. Spira, E. Winer, P. Schmid, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  11. Abstract 92912026-04-05 · 15:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-365
    A. Spira, S. Modi, S. Tolaney, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  12. Abstract 91682026-04-05 · 13:45 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-993
    M. Krop, S. Peters, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  13. Abstract 97312026-04-01 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-627 study)
    C. Saura, N. Rizvi, L. Paz-Ares, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 96832026-04-02 · 15:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with NSCLC
    S. Peters, S. Tolaney, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 96312026-04-04 · 19:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-764
    J. Cortes, S. Antonia, F. Andre, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  16. Abstract 97562026-04-03 · 13:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-258
    S. Antonia, S. Peters, C. Robert, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 95832026-04-04 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-946
    C. Robert, P. Schmid, H. Rugo, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  18. Abstract 93022026-04-02 · 15:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-960
    R. Herbst, G. Curigliano, P. Schmid, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  19. Abstract 90822026-04-05 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-653 study)
    H. Borghaei, E. Winer, S. Antonia, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  20. Abstract 95572026-04-03 · 14:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-104 study)
    S. Tolaney, M. Reck, S. Antonia, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  21. Abstract 98312026-04-04 · 14:45 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    C. Saura, J. Cortes, G. Curigliano · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  22. Abstract 92852026-04-04 · 14:30 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-941
    R. Herbst, S. Tolaney, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  23. Abstract 95932026-04-03 · 18:15 CT · S406
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-211 study)
    J. Brahmer, A. Spira · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  24. Abstract 98132026-04-02 · 14:15 CT · S406
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-331
    H. Rugo, M. Reck, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 96292026-04-01 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-146 study)
    J. Brahmer, M.C. Garassino · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  26. Abstract 94672026-04-05 · 15:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-317 study)
    H. Rugo, M.C. Garassino, C. Saura · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  27. Abstract 93122026-04-02 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    A. Spira, L. Paz-Ares, C. Saura, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 98732026-04-01 · 16:45 CT · S406
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-777
    H. Rugo, E. Winer · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  29. Abstract 97892026-04-01 · 19:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-955
    H. Borghaei, J. Brahmer, S. Modi, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  30. Abstract 92682026-04-01 · 20:15 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    M. Krop, S. Tolaney, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  31. Abstract 96032026-04-04 · 18:30 CT · Arie Crown Theater
    FLAURA-386: Tagrisso (osimertinib) adjuvant in NSCLC
    C. Saura, M. Reck · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 90832026-04-03 · 16:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-340
    C. Saura, A. Spira · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  33. Abstract 93572026-04-03 · 20:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-908
    M.C. Garassino, J. Cortes, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  34. Abstract 91442026-04-05 · 15:45 CT · S100A
    Quality of life outcomes with Imfinzi in patients with SCLC
    R. Herbst, M.C. Garassino, S. Modi · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  35. Abstract 93502026-04-05 · 21:30 CT · S406
    DESTINY-Breast-542: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    H. Rugo, L. Paz-Ares, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 90322026-04-03 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-995 study)
    S. Antonia, T. Mok, S. Modi, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  37. Abstract 97412026-04-05 · 21:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-876
    S. Antonia, R. Herbst, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  38. Abstract 93852026-04-01 · 18:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-483
    S. Peters, C. Saura, F. Andre, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 98922026-04-02 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-714 study)
    N. Rizvi, M. Krop, S. Antonia, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 93852026-04-03 · 14:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-884 study)
    M. Krop, A. Spira · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  41. Abstract 95982026-04-03 · 20:15 CT · S100A
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-443
    G. Curigliano, F. Andre, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  42. Abstract 99082026-04-01 · 15:30 CT · S406
    DESTINY-Breast-294: Enhertu (trastuzumab deruxtecan) neoadjuvant in NSCLC
    M. Reck, S. Tolaney, T. Mok · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  43. Abstract 99992026-04-04 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with SCLC
    R. Herbst, E. Winer, C. Saura, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  44. Abstract 95072026-04-02 · 16:15 CT · Arie Crown Theater
    IMpower-777: Tecentriq (atezolizumab) 3L+ in NSCLC
    H. Borghaei, S. Modi, F. Andre, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  45. Abstract 92122026-04-03 · 19:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-509 study)
    L. Paz-Ares, S. Tolaney · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  46. Abstract 94022026-04-01 · 19:15 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    P. Schmid, S. Modi, S. Peters, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  47. Abstract 94132026-04-05 · 14:45 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    L. Paz-Ares, S. Tolaney · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  48. Abstract 96142026-04-04 · 15:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-116
    H. Rugo, M.C. Garassino, F. Andre · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  49. Abstract 96762026-04-03 · 18:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-792 study)
    S. Modi, G. Curigliano · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  50. Abstract 91062026-04-03 · 15:00 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-890
    M.C. Garassino, M. Krop, A. Spira · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  51. Abstract 98712026-04-01 · 20:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-905
    N. Rizvi, S. Modi, S. Tolaney · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 98082026-04-04 · 13:15 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    G. Curigliano, M. Krop, H. Rugo, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  53. Abstract 90842026-04-04 · 14:45 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-498
    N. Rizvi, M. Reck · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  54. Abstract 95522026-04-03 · 18:00 CT · E450
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-399
    M. Reck, L. Paz-Ares, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  55. Abstract 99312026-04-05 · 18:00 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-878 study)
    C. Saura, M. Reck, S. Tolaney, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  56. Abstract 95512026-04-03 · 18:45 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    S. Antonia, A. Spira · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  57. Abstract 99162026-04-02 · 15:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-650
    M. Krop, F. Andre, A. Spira · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  58. Abstract 99582026-04-01 · 21:15 CT · Hall B1
    PACIFIC-847: Imfinzi (durvalumab) 1L in SCLC
    E. Winer, A. Spira · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  59. Abstract 93562026-04-01 · 21:30 CT · E450
    PACIFIC-77: Imfinzi (durvalumab) maintenance in NSCLC
    J. Cortes, T. Mok · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  60. Abstract 90712026-04-03 · 19:15 CT · S406
    FLAURA-119: Tagrisso (osimertinib) neoadjuvant in NSCLC
    R. Herbst, H. Rugo · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  61. Abstract 93722026-04-01 · 20:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-966
    M. Reck, H. Rugo · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  62. Abstract 96182026-04-04 · 15:45 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-508 study)
    H. Borghaei, M. Reck, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  63. Abstract 98512026-04-01 · 21:00 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    L. Paz-Ares, S. Tolaney, G. Curigliano, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  64. Abstract 97082026-04-02 · 21:15 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-709
    P. Schmid, H. Borghaei, L. Paz-Ares · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  65. Abstract 96252026-04-01 · 14:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-971
    P. Schmid, S. Peters, J. Brahmer · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  66. Abstract 96012026-04-01 · 18:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-671
    F. Andre, S. Peters, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  67. Abstract 99092026-04-01 · 21:30 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-41
    S. Antonia, S. Peters, J. Brahmer, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  68. Abstract 94022026-04-04 · 19:30 CT · Hall B1
    FLAURA-963: Tagrisso (osimertinib) 2L in NSCLC
    E. Winer, N. Rizvi, J. Brahmer, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  69. Abstract 97112026-04-04 · 21:00 CT · Arie Crown Theater
    KEYNOTE-213: Keytruda (pembrolizumab) neoadjuvant in NSCLC
    L. Paz-Ares, F. Andre, C. Robert, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  70. Abstract 97762026-04-03 · 18:00 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-714
    S. Modi, M. Krop, C. Saura, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  71. Abstract 91942026-04-02 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-197 study)
    G. Curigliano, M. Reck, S. Peters, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  72. Abstract 97602026-04-01 · 16:15 CT · E450
    Quality of life outcomes with Enhertu in patients with NSCLC
    E. Winer, S. Tolaney, C. Robert, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  73. Abstract 99482026-04-01 · 20:45 CT · E450
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-331
    H. Rugo, M. Reck · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  74. Abstract 97982026-04-03 · 14:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-648
    C. Saura, T. Mok, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  75. Abstract 97052026-04-02 · 14:30 CT · Arie Crown Theater
    FLAURA-308: Tagrisso (osimertinib) maintenance in NSCLC
    L. Paz-Ares, M. Krop, S. Antonia · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  76. Abstract 98082026-04-05 · 18:45 CT · Hall B1
    FLAURA-205: Tagrisso (osimertinib) 2L in NSCLC
    E. Winer, L. Paz-Ares, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  77. Abstract 94442026-04-03 · 14:30 CT · Arie Crown Theater
    PACIFIC-436: Imfinzi (durvalumab) 1L in SCLC
    T. Mok, P. Schmid, S. Modi · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  78. Abstract 97872026-04-02 · 20:45 CT · S406
    FLAURA-582: Tagrisso (osimertinib) maintenance in NSCLC
    E. Winer, S. Peters, S. Modi · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  79. Abstract 92062026-04-02 · 20:15 CT · S100A
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-148
    L. Paz-Ares, S. Modi, N. Rizvi, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  80. Abstract 99192026-04-01 · 13:30 CT · E450
    KEYNOTE-38: Keytruda (pembrolizumab) maintenance in NSCLC
    M.C. Garassino, A. Spira, M. Krop, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  81. Abstract 94742026-04-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-220 study)
    C. Saura, J. Brahmer · Karolinska Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  82. Abstract 94212026-04-01 · 18:00 CT · S406
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-324
    M. Krop, H. Rugo, T. Mok · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  83. Abstract 92862026-04-02 · 19:00 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-558 study)
    G. Curigliano, T. Mok, H. Rugo, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  84. Abstract 96232026-04-02 · 14:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-637
    P. Schmid, S. Peters · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  85. Abstract 90962026-04-05 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-110 study)
    L. Paz-Ares, C. Robert · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  86. Abstract 92072026-04-03 · 15:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-216 study)
    S. Antonia, E. Winer, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  87. Abstract 99752026-04-05 · 16:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)
    C. Robert, S. Peters, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  88. Abstract 91382026-04-04 · 13:45 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-386
    N. Rizvi, M. Krop, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  89. Abstract 95322026-04-02 · 13:00 CT · Hall B1
    CheckMate-291: Opdivo (nivolumab) adjuvant in NSCLC
    M.C. Garassino, C. Robert, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  90. Abstract 91572026-04-05 · 18:15 CT · E450
    KEYNOTE-291: Keytruda (pembrolizumab) 3L+ in SCLC
    J. Cortes, S. Tolaney, M. Reck, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  91. Abstract 91812026-04-01 · 21:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-623 study)
    L. Paz-Ares, A. Spira, P. Schmid · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  92. Abstract 90812026-04-01 · 14:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-915
    J. Cortes, M. Krop, C. Saura · Mayo Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.